Opus Genetics
IRD
38 hedge funds and large institutions have $3.32M invested in Opus Genetics in 2024 Q3 according to their latest regulatory filings, with 7 funds opening new positions, 7 increasing their positions, 10 reducing their positions, and 6 closing their positions.
1,700% more call options, than puts
Call options by funds: $18K | Put options by funds: $1K
17% more first-time investments, than exits
New positions opened: 7 | Existing positions closed: 6
3% more funds holding
Funds holding: 37 → 38 (+1)
0.74% less ownership
Funds ownership: 10.4% → 9.66% (-0.74%)
20% less capital invested
Capital invested by funds: $4.13M → $3.32M (-$810K)
30% less repeat investments, than reductions
Existing positions increased: 7 | Existing positions reduced: 10
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citadel Advisors
Miami,
Florida
|
+$112K |
| 2 |
Renaissance Technologies
New York
|
+$44.5K |
| 3 |
XT
XTX Topco
George Town,
Cayman Islands
|
+$42.9K |
| 4 |
VF
Virtu Financial
New York
|
+$36.5K |
| 5 |
RJA
Raymond James & Associates
St Petersburg,
Florida
|
+$18.1K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
RHJA
Rice Hall James & Associates
San Diego,
California
|
-$342K |
| 2 |
Jane Street
New York
|
-$64.8K |
| 3 |
RB
Richmond Brothers
Jackson,
Michigan
|
-$54.9K |
| 4 |
Royal Bank of Canada
Toronto,
Ontario, Canada
|
-$33.8K |
| 5 |
UBS Group
Zurich,
Switzerland
|
-$15.4K |
IRD Hedge Fund Activity: Q3 2024 in Review
38 of the 6,964 institutional investors tracked by Wall St. Rank reported a position in Opus Genetics (IRD) for Q3 2024, worth a combined $3.32M — down 20% from $4.13M a quarter earlier.
Buyers outnumbered sellers: 7 funds opened new IRD positions and 6 closed out — a net gain of 1 holder — while 7 added to existing stakes and 10 trimmed.
The largest buyer was Citadel Advisors, adding an estimated $112K. The largest seller was Rice Hall James & Associates, exiting entirely with an estimated $342K sold.
- 38 institutional investors held Opus Genetics (IRD) as of Q3 2024, up from 37 in Q2 2024.
- Funds reported $3.32M of Opus Genetics stock for Q3 2024, down 20% quarter-over-quarter.
- 7 funds opened new Opus Genetics positions in Q3 2024 and 6 closed out, a net change of +1 holder.
- The largest Opus Genetics buyer in Q3 2024 was Citadel Advisors, an estimated $112K added.
- The largest Opus Genetics seller in Q3 2024 was Rice Hall James & Associates, an estimated $342K sold.
Based on aggregated 13F filings for Q3 2024.